Collectively, these data suggest that the induction of IL21R by CpG-685 may play a role in the potential therapeutic effects of combined CpG ODN and IL-21 as a novel immune therapeutic approach for CLL. The gene discussed is IL21R; the disease is B-cell chronic lymphocytic leukemia.